Physician profile
Thomas D Yates
NPI 1225012446
$8,881.46
in general payments reported to CMS, 2019-2025
46 companies · $1,022 in 2025
The $1,022 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,287 · 2020: $1,259 · 2021: $1,157 · 2022: $1,596 · 2023: $1,480 · 2024: $1,081 · 2025: $1,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,581.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,041.52 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $922.84 | 2019-2025 | Farxiga, Airsupra |
| Abbvie INC. | $769.27 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $738.89 | 2019-2025 | Otezla, Repatha, Evenity |
| Novo Nordisk INC | $703.28 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $696.36 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $538.86 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $526.82 | 2021-2025 | |
| Lilly USA, LLC | $465.22 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $246.35 | 2019-2025 | |
| Corcept Therapeutics | $214.12 | 2019-2025 | Korlym |
| Indivior INC. | $178.74 | 2024-2025 | Sublocade |
| Janssen Pharmaceuticals, INC | $178.57 | 2019-2022 | |
| Glaxosmithkline, LLC. | $139.33 | 2019-2024 | Trelegy Ellipta, Menveo, Bexsero |
| Astellas Pharma US INC | $125.14 | 2019-2021 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Yates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.